ReviewClinical reviews in allergy & immunology2005
Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
Review in Clinical reviews in allergy & immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- [Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- A Pelvic Mass in a Young Patient With Crohn's Disease.ACG case reports journal · 2025Article
- Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- A Rare Case of Rheumatoid Arthritis with Tocilizumab-induced Intestinal Mucosal Injury.Internal medicine (Tokyo, Japan) · 2022Article
- Profile of tocilizumab and its potential in the treatment of giant cell arteritis.Eye and brain · 2018Review
- Hyaline-Vascular Type Castleman's Disease, Sarcoidosis, and Crohns Disease.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016Article
- Review
- Targeting Inflammation Through a Physical Active Lifestyle and Pharmaceuticals for the Treatment of Type 2 Diabetes.Current diabetes reports · 2015Review
- Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.Melanoma research · 2015Article
- Current and potential treatments for ubiquitous but neglected herpesvirus infections.Chemical reviews · 2014Review
- Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure.Current heart failure reports · 2014Review
- Article
- IL-6 receptor is a possible target against growth of metastasized lung tumor cells in the brain.International journal of molecular sciences · 2012Article
- Castleman disease.The Korean journal of hematology · 2012Article
- Castleman's disease: from basic mechanisms to molecular therapeutics.The oncologist · 2011Review
- Antibody-based therapies in multiple myeloma.Bone marrow research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-6 is a pleiotropic cytokine with a wide range of biological activities and regulates immunological reactions, inflammatory responses, and hematopoiesis. Overproduction of IL-6 has been shown to be pathologically involved in some inflammatory diseases, such as Castleman's disease, Crohn's disease, and rheumatoid arthritis. Clinical studies have been conducted to investigate a role of IL-6 and the therapeutic potential of anti-IL-6 therapy for these diseases using humanized anti-IL-6 receptor antibody (tocilizumab; currently known as MRA). Overall, tocilizumab was well-tolerated, and improvements of signs and symptoms were observed, confirming the pathological role of IL-6 and suggesting that the blockade of IL-6 could become a new and important treatment option in these refractory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.